2003 Highlights From: 39th Annual Meeting of the American Society of Clinical Oncology Chicago, Illinois May 31 to June 3, 2003

References

1. • Kimmick GG
   • Muss HB
   Systemic therapy for older women with breast cancer.
   Oncology (Huntingt). 2001; 15: 280-291
   • PubMed
   • Google Scholar
2. Multi-agent chemotherapy for early breast cancer (Cochrane Review).
   Cochrane Database Syst Rev. 2002;
   • Google Scholar
3. • Early Breast Cancer Trialists' Collaborative Group
   Polychemotherapy for early breast cancer: an overview of the randomised trials.
   Lancet. 1998; 352: 930-942
   • Scopus (2044)
   • PubMed
   • Abstract
   • Full Text
   • Full Text PDF
   • Google Scholar
4. • Muss H
   • Woolf S
   • Berry D
   • et al.
   Older Women with Node-Positive (N+) Breast Cancer (BC).
   Proc Am Soc Clin Oncol. 2003; 22 (Abstract #11).: 4
   • PubMed
   • Google Scholar
5. • Coleman RE
   Current and future status of adjuvant therapy for breast cancer.
   Cancer. 2003; 97: 880-886
   • Scopus (44)
   • PubMed
   • Crossref
   • Google Scholar
6. • Cocconi G
   • Di Blasio B
   • Boni C
   • et al.
   Randomized trial comparing cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) with rotational CMF, epirubicin and vincristine as primary chemotherapy in operable breast carcinoma.
   Cancer. 2002; 95: 228-235
   • Scopus (6)
   • PubMed
   • Crossref
   • Google Scholar
7. • Levine MN
   • Bramwell VH
   • Pritchard KI
   • et al.
   Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute Canada Clinical Trials Group.
   J Clin Oncol. 1998; 16: 2651-2658
   • Scopus (523)
   • PubMed
   • Crossref
   • Google Scholar
8. • Mouridsen HT
   • Andersen J
   • Andersson M
   • et al.
   Adjuvant Anthracycline in Breast Cancer: Improved Outcome in Premenopausal Patients Following Substitution of Methotrexate in the CMF Combination with Epirubicin.
   Proc Am Soc Clin Oncol. 1999; 18 (Abstract #254).: 68a
   • Google Scholar
9. • Poole CJ
   • Earl HM
   • Dunn JA
   • et al.
   NEAT (National Epirubicin Adjuvant Trial) and SCTBG BR9601 (Scottish Cancer Trials Breast Group) phase III adjuvant breast trials show a significant relapse-free and overall survival advantage for sequential ECMF.
   Proc Am Soc Clin Oncol. 2003; 22 (Abstract #13).: 4
   • PubMed
   • Google Scholar
10. • Nole F
    • Munzone E
    • Orlando L
    • et al.
    First Line Chemotherapy for Metastatic Breast Cancer (MBC): A Regimen with a Low Subjective Toxic Burden Containing Vinorelbine (V), Continuous Infusion 5-fluorouracil (ci FU) and Cisplatin (P) (ViFuP).
    Proc Am Soc Clin Oncol. 1999; 18 (Abstract # 429).: 113a
    • Google Scholar
11. • Vogel C
    • Hochster H
    • Blumenreich M
    • et al.
    A US multicenter phase II study of IV Navelbine (NVB) and 5-fluorouracil (5FU) as first line treatment of patients with advanced breast cancer (ABC).
    Proc Am Soc Clin Oncol. 1995; 14 (Abstract #62).: 91
    • Google Scholar
12. • Berruti A
    • Sperone P
    • Bottini A
    • et al.
    Phase II study of vinorelbine with protracted fluorouracil infusion as a second- or third-line approach for advanced breast cancer patients previously treated with anthracyclines.
    J Clin Oncol. 2000; 18: 3370-3377
    • PubMed
    • Google Scholar
13. • Ahn J
    • Kim S
    • Ahn S
    • et al.
    Phase II study of capecitabine and vinorelbine in anthracycline and taxane pretreated breast cancer patients: Final results.
    Proc Am Soc Clin Oncol. 2003; 22 (Abstract #216).: 54
    • Google Scholar
14. • Stuart N
    • Bishop J
    • Johnson SRD
    • et al.
    Vinorelbine and capecitabine (VX) for advanced breast cancer - a phase II study showing good activity and potential for further development.
    Proc Am Soc Clin Oncol. 2003; 22 (Abstract #183).: 46
    • Google Scholar
15. • Welt A
    • von Minckwitz G
    • Borquez D
    • et al.
    Extended phase I study of capecitabine in combination with vinorelbine in pretreated patients with advanced breast cancer.
    Breast Cancer Res and Treat. 2002; (Abstract #336).: 76
    • Google Scholar
16. • Ghosn M
    • Farhat F
    • Kattan J
    • et al.
    Final results of a phase II study of vinorelbine in combination with capecitabine as first line chemotherapy for metastatic breast cancer (MBC).
    Proc Am Soc Clin Oncol. 2003; 22 (Abstract #270).: 68
    • Google Scholar
17. • Von Minckwitz G
    • Raab G
    • Blohmer J
    • et al.
    Primary chemotherapy adapted on in vivo chemosensitivity in patients with primary breast cancer. The pilot GEPARTRIO study.
    Proc Am Soc Clin Oncol. 2003; 22 (Abstract #85).: 22
    • Google Scholar
18. • Milla-Santos A
    • Milla L
    • Rallo L
    • et al.
    Phase III randomized trial of toremifene vs tamoxifen in hormonodependant advanced breast cancer.
    Breast Cancer Res Treat. 2001; 65: 119-124
    • Scopus (54)
    • PubMed
    • Crossref
    • Google Scholar
19. • Kitchen PR
    • Smith TH
    • Henderson MA
    • et al.
    Tubular carcinoma of the breast: prognosis and response to adjuvant systemic therapy.
    Aust N Z J Surg. 2001; 71: 27-31
    • Scopus (30)
    • Crossref
    • Google Scholar
20. • Pagani O
    • Gelber S
    • Simoncini E
    • et al.
    Randomized comparison of adjuvant toremifene (Tor) versus tamoxifene (Tam) for postmenopausal women with node-positive (N+) estrogen receptor-positive (ER+) early stage breast cancer.
    Proc Am Soc Clin Oncol. 2003; 22 (Abstract #79).: 20
    • Google Scholar
21. • Shibutani S
    • Ravindernath A
    • Terashima I
    • et al.
    Mechanism of lower genotoxicity of toremifene compared with tamoxifen.
    Cancer Res. 2001; 61: 3925-3931
    • PubMed
    • Google Scholar
22. • Holli K
    • Valavaara R
    • Blanco G
    • et al.
    Safety and efficacy results of a randomized trial comparing adjuvant toremifene and tamoxifen in postmenopausal patients with nodepositive breast cancer. Finnish Breast Cancer Group.
    J Clin Oncol. 2000; 18: 3487-3494
    • PubMed
    • Google Scholar
23. • Holli K
    Tamoxifen versus toremifene in the adjuvant treatment of breast cancer.
    Eur J Cancer. 2002; 38: S37-S38
    • PubMed
    • Abstract
    • Full Text
    • Full Text PDF
    • Google Scholar
24. • Miyauchi K
    • Sano M
    • Kimura M
    • et al.
    Effect of toremifene (TOR) and tamoxifen (TAM) on serum lipids in postmenopausal patients with breast cancer.
    Proc Am Soc Clin Oncol. 2003; 22 (Abstract #165).: 41
    • Google Scholar
25. • Nordenskjold B
    • Rutqvist L
    • Malmstrom J
    • et al.
    The Swedish Breast Cancer Group trial of two versus five years of adjuvant tamoxifen: disease recurrence, cause-specific mortality and primary malignancies.
    Proc Am Soc Clin Oncol. 2003; 22 (Abstract #60).: 16
    • Google Scholar
26. • Slamon DJ
    • Leyland-Jones B
    • Shak S
    • et al.
    Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
    N Engl J Med. 2001; 344: 783-792
    • Scopus (9374)
    • PubMed
    • Crossref
    • Google Scholar
27. • Sparano JA
    • Malik U
    • Rajdev L
    • et al.
    Phase I trial of pegylated liposomal doxorubicin and docetaxel in advanced breast cancer.
    J Clin Oncol. 2001; 19: 3117-3125
    • Scopus (65)
    • PubMed
    • Crossref
    • Google Scholar
28. • Wolff A
    • Bonetti M
    • Sparano JA
    • et al.
    Cardiac Safety of Trastuzumab (H) in Combination with Pegylated Liposomal Doxorubicin (D) and Docetaxel (T) in HER2-Positive Metastatic Breast Cancer (MBC): Preliminary Results of ECOG 3198.
    Proc Am Soc Clin Oncol. 2003; 22 (Abstract #70).: 18
    • Google Scholar